Nektar Therapeutics (NKTR) Change in Accured Expenses (2010 - 2026)

Nektar Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 91.44% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was -$4.7 million, a 146.14% decrease from a year earlier, with the FY2025 full-year figure at -$5.8 million, down 153.9% from the prior year.
• Change in Accured Expenses advanced to $2.3 million in Q1 2026 per NKTR's latest filing, from -$2.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $14.2 million in Q1 2022 and bottomed at -$21.5 million in Q4 2022.
• The 5-year median for Change in Accured Expenses is $412000.0 (2023), against an average of -$1.8 million.
• Across the five-year window, Change in Accured Expenses plunged 770.7% in 2023 and soared 1489.56% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at -$21.5 million in 2022, then surged by 54.77% to -$9.7 million in 2023, then surged by 32.45% to -$6.6 million in 2024, then surged by 58.64% to -$2.7 million in 2025, then soared by 185.42% to $2.3 million in 2026.
• Per Business Quant, the three latest NKTR Change in Accured Expenses figures stand at $2.3 million (Q1 2026), -$2.7 million (Q4 2025), and -$7.0 million (Q3 2025).